Overview

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.
Phase:
Phase 3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Thyrotropin-Releasing Hormone